Bortezomib was found to activate CEBPD (CCAAT/enhancer binding protein delta), a transcription factor associated with cellular differentiation, motility and cell death, thereby functioning as a tumor suppressor in various cancers by promoting apoptosis and cell cycle arrest [133]. Here, CEBPD is linked to cancer.